Thromboembolic Complications Post-COVID-19: What is the Risk in Mild-Moderate Cases?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 961
- Locations
- 1
- Primary Endpoint
- The frequency of thromboembolic complications in COVID-19 patients not requiring hospitalization.
Study Overview
Brief Summary
The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization. For this purpose, patients registered at two different family health centers in Istanbul were retrospectively screened, and their status regarding post-COVID-19 thromboembolic events was recorded. The sociodemographic characteristics, medical history, COVID-19 treatments received, comorbidities, and current medications of all patients were examined and compared with the occurrence of complications.
Detailed Description
Studies on COVID-19 complications in the literature have predominantly focused on patients treated in hospitals, particularly in intensive care units. Data on patients with mild to moderate symptoms who were followed up on an outpatient basis in primary care are quite limited. Therefore, our research investigated the incidence of thrombotic events within six months following infection in mild to moderate COVID-19 cases and the factors that might influence these events. Records of 961 individuals registered at two different family health centers in Istanbul were reviewed. Patients were contacted by phone, informed about the study, and data regarding their sociodemographic characteristics, medical histories, COVID-19 infection experiences, and medications used were collected. Comparative analyses (Fisher's exact test) and logistic regression tests were conducted.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Being over 18 years of age
- •Having had a confirmed COVID-19 infection verified by a PCR test
- •Being monitored at a family health center without requiring hospitalization during the COVID-19 course
- •Having at least 6 months elapsed since the infection
- •Availability of the patient's medical records
- •Absence of any language barrier or health issue that would prevent communication with the patient
Exclusion Criteria
- •Being under 18 years of age
- •Having had less than 6 months since the COVID-19 infection
- •Presence of any condition that prevents communication with the patient
- •Incomplete or missing medical records of the patient
- •History of hospitalization due to COVID-19 infection
Outcomes
Primary Outcomes
The frequency of thromboembolic complications in COVID-19 patients not requiring hospitalization.
Time Frame: january-june 2022
Patients registered at a family health center were retrospectively reviewed, and those with a history of COVID-19 PCR positivity who had been followed up as outpatients were included. The occurrence of venous or arterial thromboembolism within the first 6 months after infection was recorded from their medical reports, and the frequency was calculated.
The relationship between patients' comorbidities and the occurrence of thromboembolic events post-COVID.
Time Frame: january-june 2022
The patients' existing chronic conditions from the time of their COVID-19 infection were recorded by reviewing the family medicine system. The presence of chronic diseases was then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.
The relationship between patients' medications and the occurrence of thromboembolic events post-COVID.
Time Frame: january-june 2022
The medications regularly used by patients for their chronic conditions since the time of their COVID-19 infection were noted by reviewing records in the family medicine system. These medications were then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.
Secondary Outcomes
No secondary outcomes reported
Investigators
Buğu Usanma Koban
MD, PhD
Marmara University Pendik Training and Research Hospital